Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is there a need for "triple therapy"? Role of anticoagulation with dual antiplatelet therapy in acute coronary syndromes (ATLAS Study & TRAP Study).
Patrick WL, Patel C, Guddeti R, Narayan A, Maddaleni M, Kumar S, Dolma K, Serla VV, Sangha M, Govindavarjhulla A, Saddala P, Singh P, Halaby R, Gibson CM. Patrick WL, et al. Among authors: gibson cm. Curr Cardiol Rep. 2013 Oct;15(10):411. doi: 10.1007/s11886-013-0411-1. Curr Cardiol Rep. 2013. PMID: 24022544 Review.
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: gibson cm. J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24. doi: 10.1016/j.jacc.2005.08.024. J Am Coll Cardiol. 2005. PMID: 16226164 Free article. Clinical Trial.
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group. Gibson CM, et al. J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73. doi: 10.1016/j.jacc.2005.12.077. J Am Coll Cardiol. 2006. PMID: 16781360 Free article. Clinical Trial.
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).
Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP; TIMI Study Group. Gibson CM, et al. Am J Cardiol. 2006 Sep 15;98(6):761-3. doi: 10.1016/j.amjcard.2006.03.062. Epub 2006 Aug 2. Am J Cardiol. 2006. PMID: 16950180
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Wiviott SD, et al. Among authors: gibson cm. Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012. Am Heart J. 2006. PMID: 16996826 Clinical Trial.
Enoxaparin in acute coronary syndromes.
Lee S, Gibson CM. Lee S, et al. Among authors: gibson cm. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99. doi: 10.1586/14779072.5.3.387. Expert Rev Cardiovasc Ther. 2007. PMID: 17489664 Review.
781 results